Regeneron Is a Late Entrant in Immuno-Oncology Space



Regeneron’s approach towards immuno-oncology space

Immuno-oncology has been quite an interesting area with increasing innovation and a lot of new developments. The checkpoint inhibitors seem to be the foundation for immuno-oncology therapy. Although Regeneron (REGN) hasn’t been a leader in the immuno-oncology space and in fact it’s a late entrant in the game, it’s exploring a couple of approaches in the space.

Its first approach includes building combination therapies and new modalities upon its PD-1 (programmed cell death protein 1) antibody candidate. Regeneron is conducting research on the PD-1 antibody in cutaneous squamous cell carcinoma.

Article continues below advertisement

Another approach is the bispecific platform. With CD3/CD20 antibody as the lead candidate in the clinic, REGN is exploring the candidate as monotherapy as well as combination therapy with the PD-1 antibody. Regeneron’s collaboration with Adicet for exploring immune cell therapies or precision immunotherapy has been an area of interest for the company.

Regeneron and Sanofi are exploring immuno-oncology space

Regeneron has an established relationship with Sanofi (SNY) to explore the immuno-oncology space. It’s developing REGN-2810 for the indication of cancer and in combination with REGN-1979 for lymphoma or acute lymphoblastic leukemia in association with Sanofi.

Other major companies that operate in the immuno-oncology space include Roche (RHHBY), Novartis (NVS), and Pfizer.

It’s often risky to directly invest in a high-growth biotechnology company. Although these companies might offer a higher return, there is higher risk. Thus, you could consider investing in the iShares Nasdaq Biotechnology ETF (IBB). Regeneron accounts for 5.5% of the fund’s total assets. Next, let’s look at analyst recommendations for REGN.


More From Market Realist